- Home
- AQST vs IVA Comparison
AQST vs IVA Comparison
Compare AQST & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQST
- IVA
- Stock Information
- Founded
- AQST 2004
- IVA 2011
- Country
- AQST United States
- IVA France
- Employees
- AQST N/A
- IVA N/A
- Industry
- AQST Biotechnology: Pharmaceutical Preparations
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- AQST Health Care
- IVA Health Care
- Exchange
- AQST Nasdaq
- IVA Nasdaq
- Market Cap
- AQST 390.4M
- IVA 359.6M
- IPO Year
- AQST 2018
- IVA 2020
- Fundamental
- Price
- AQST $3.96
- IVA $3.31
- Analyst Decision
- AQST Strong Buy
- IVA Strong Buy
- Analyst Count
- AQST 7
- IVA 4
- Target Price
- AQST $11.29
- IVA $10.50
- AVG Volume (30 Days)
- AQST 1.1M
- IVA 19.9K
- Earning Date
- AQST 08-11-2025
- IVA 09-24-2025
- Dividend Yield
- AQST N/A
- IVA N/A
- EPS Growth
- AQST N/A
- IVA N/A
- EPS
- AQST N/A
- IVA N/A
- Revenue
- AQST $54,228,000.00
- IVA $14,591,573.00
- Revenue This Year
- AQST N/A
- IVA $44.22
- Revenue Next Year
- AQST $51.62
- IVA $24.23
- P/E Ratio
- AQST N/A
- IVA N/A
- Revenue Growth
- AQST 5.29
- IVA N/A
- 52 Week Low
- AQST $2.12
- IVA $1.53
- 52 Week High
- AQST $5.80
- IVA $4.05
- Technical
- Relative Strength Index (RSI)
- AQST 50.64
- IVA 52.15
- Support Level
- AQST $3.73
- IVA $3.16
- Resistance Level
- AQST $4.10
- IVA $3.58
- Average True Range (ATR)
- AQST 0.22
- IVA 0.25
- MACD
- AQST -0.07
- IVA 0.00
- Stochastic Oscillator
- AQST 17.42
- IVA 62.83
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.